Skip to main content

Table 1 Cytotoxicity of Guieranone A and Doxorubicin in various cancer cell lines

From: Cytotoxicity, anti-angiogenic, apoptotic effects and transcript profiling of a naturally occurring naphthyl butenone, guieranone A

Cell lines

Sample and IC 50values

Guieranone A

 

Doxorubicin

 

 

 

μg/ml

μM

μg/ml

μM

CCRF-CEM

0.73 ± 0.11

2.31 ± 0.35

0.62 ± 0.003

1.14 ± 0.005

CEM/ADR5000

1.01 ± 0.09 (1.38)

3.19 ± 0.28

>20 (>32.26)

>36.8

MiaPaCa-2

3.91 ± 0.25

12.37 ± 0.79

0.95 ± 0.06

1.75 ± 0.11

Capan-1

9.19 ± 2.29

29.08 ± 7.24

4.06 ± 1.18

7.47 ± 2.17

MCF-7

1.08 ± 0.32

3.42 ± 0.90

0.59 ± 0.05

1.08 ± 0.09

SW-680

>20

>63.29

0.93 ± 0.09

1.71 ± 0.17

786-0

3.68 ± 0.54

11.32 ± 1.70

0.60 ± 0.09

1.10 ± 0.17

U87MG

2.46 ± 0.02

7.78 ± 0.05

0.37 ± 0.08

0.68 ± 0.14

A549

0.72 ± 0.07

2.28 ± 0.22

1.69 ± 0.05

3.11 ± 0.09

Colo-38

2.43 ± 0.75

7.69 ± 1.38

0.81 ± 0.06

1.49 ± 0.11

HeLa

0.51 ± 0.04

1.61 ± 0.13

0.26 ± 0.02

0.48 ± 0.04

Caski

1.18 ± 0.11

3.73 ± 0.35

0.58 ± 0.02

1.07 ± 0.04

AML12 (EC50)*

>20

>63.29

>20

>36.8

  1. ac*EC50: effective dose showing 50% inhibition of growth proliferation.